-
The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets
Time of Update: 2023-01-06
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
-
The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets
Time of Update: 2023-01-06
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
The listing of this drug provides a treatment option for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
-
Sinovac Pharmaceutical joins hands with Tonghua Dongbao to add new products to overseas commercialization
Time of Update: 2022-12-30
The strength of overseas commercialization is highlightedIn recent years, with the strengthening of overseas high-quality biopharmaceutical market demand, Sinovac Pharmaceutical has actively established strategic cooperation with domestic and foreign biotechnology companies by relying on more than 20 years of accumulated commercialization experience, global three-dimensional marketing network and channel resources, and rapid overseas registration capabilities.
-
Jasmine tea, roast chicken, mung bean cake... Shandong's 21 batches of unqualified food announced six major categories of problems need attention
Time of Update: 2022-12-29
, Ltd. re-inspection agency: Jinan Fruit Research Institute of All-China Supply and Marketing Cooperative/National Fruit and Vegetable and Processing Product Quality Inspection and Testing Center The retest failed 10 Rice cake (puffed food) / / Dezhou Economic and Technological Development Zone Dolofour daily department store Xiaozhao Village, Futousi Town, Economic and Technological Development Zone, Dezhou City, Shandong Province 120g/bag / 2022/2/19 Moisture || 11.
-
The State Food and Drug Administration approved the marketing of torudibin lafaxine hydrochloride sustained-release tablets
Time of Update: 2022-11-15
The launch of the drug provides more treatment options for patients with depression.
The launch of the drug provides more treatment options for patients with depression.
The launch of the drug provides more treatment options for patients with depression.
-
In November, a number of new drug clinical applications have been approved
Time of Update: 2022-11-15
On November 2, Acro Biotech announced that the clinical trial application of the new PD-L1/4-1BB bispecific antibody "HK010 injection" with independent intellectual property rights has been approved by the State Food and Drug Administration and is intended to be used for the treatment of advanced malignant tumors.
-
PD-(L)1 Clinical Development Challenges and Opportunities: Over 80% of Combination Therapy in Nearly 5,000 Clinical Trials
Time of Update: 2022-03-07
(Source: Nature Reviews Drug Discovery)As anti-PD1/PDL1 clinical trials continue to move toward a combined strategy, the authors update their analysis of the targets pursued by such models .
-
Pfizer Ogaituzumab for Injection Approved in China to Treat Leukemia
Time of Update: 2021-12-24
Retrieved Dec 22, 2021, from https:// Information to be obtained for the drug approval certificate issued by the State Drug Administration of China on December 22.
-
SHPL-49 injection, a new class 1 chemical drug of Shanghai Hutchison Pharmaceuticals, obtained NMPA and FDA clinical trial approval
Time of Update: 2021-11-04
The SHPL-49 injection was approved for clinical trials in China and the United States, marking the staged success of the collaborative innovation and achievement transformation of Shanghai University of Traditional Chinese Medicine and Shanghai Hutchison Pharmaceuticals .
-
Haichen Pharmaceutical's Entecavir Tablets Obtained Drug Registration Approval
Time of Update: 2021-08-16
On the 28th, Haichen Pharmaceutical announced that the company’s entecavir tablets had recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration .
Entecavir tablets are a guanosine analogue, which has an inhibitory effect on hepatitis B virus (HBV) polymerase .
-
Qinhao Pharmaceutical obtained the first IND approval in China
Time of Update: 2021-06-22
The clinical approval of this drug means that Qin Hao Pharmaceutical has obtained the first IND approval in China .
-
Target the root cause of complement diseases
Time of Update: 2021-06-22
The results of another open-label phase II study (NCT03439839) previously published in the "Lancet Hematology" showed that PNH with active hemolysis after receiving standard care therapy (C5 inhibitor Soliris [eculizumab]) In patients, iptacopan as an add-on therapy significantly improved the hematological response and biomarkers of disease activity .
-
FDA approved this year's 25th new drug approval speed hits a record high over the same period
Time of Update: 2021-06-18
Scynexis announced that the US FDA has approved the innovative oral glucan synthase inhibitor Brexafemme (ibrexafungerp) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection).
-
Review of Shanghai Pharmaceutical Cimetidine Tablets and Perindopril Tert-butylamine Tablets
Time of Update: 2021-05-21
On May 12, Shanghai Pharmaceuticals issued an announcement stating that its wholly-owned subsidiary received the "Notice of Approval of Supplementary Application for Drugs" issued by the State Food and Drug Administration regarding cimetidine tablets and perindopril tert-butylamine tablets (4mg, 2mg) , The above-mentioned drugs have passed the quality and efficacy consistency evaluation of generic drugs.
-
Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization
Time of Update: 2021-05-02
On April 14, Suoyuan Biopharmaceuticals and Rumpus Therapeutics/Aytu Biopharma signed a global license agreement for the development of DB102 (enzastaurin) for the treatment of vascular Ehlers-Danglos syndrome (vEDS) and other rare genetic diseases.
